Company intelligence / Profile preview

Anyra Biotech

Schlieren, Zurich, Switzerland

Ownership: Private
Development stage: Other

Overview

Anyra Biotech is a Swiss biopharmaceutical company focused on developing next-generation cancer immunotherapies that target the tumor microenvironment. The company was founded in 2022 by a team of seasoned biotech executives, including former leaders from Covagen, which was acquired by Janssen. Anyra's lead candidate, ANY-001, is a bispecific antibody designed to inhibit both CD39 and CD73, effectively blocking the production of immunosuppressive adenosine in tumors. This dual-targeting approach is intended to enhance the activity of T cells and other immune cells within the tumor. The company is currently advancing its pipeline through preclinical development to address unmet needs in solid tumor oncology.

Therapeutic areas: Oncology
Modalities: Bispecific monoclonal antibodyMonoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on Anyra Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anyra Biotech.

Explore the full profile